Boston Scientific is scheduled to report third-quarter 2026 results, with analysts expecting earnings of about 72 cents per share on $5.06 billion in revenue—below the company’s stated quarterly earnings guidance of 80 to 82 cents per share. In its most recent reported quarter, the medical-device maker exceeded earnings and revenue estimates, while year-over-year revenue increased 7.5%. Analysts’ overall stance remains positive, with a “Moderate Buy” consensus among 31 firms, although several have lowered their price targets. The stock fell for a third straight session Tuesday, slipping 1.14% to $45.06 even as major U.S. indexes rose.
What each side asserts, disputes — or leaves out entirely.
Whose framing of this story rings truest to you?
